COX-2–selective inhibitors in the treatment of arthritis

Thomas J. Schnitzer, MD, PhD
Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago

Marc C. Hochberg, MD, MPH
Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore

Correspondence: Thomas J. Schnitzer, MD, PhD, Professor of Medicine, Director, Office of Clinical Research and Training, Northwestern University School of Medicine, 710 North Lake Shore Drive, 10th Floor, Chicago, IL 60611; e-mail: tjs@nwu.edu

Dr. Schnitzer has indicated that he has received clinical research support from Merck & Co., Inc., Novartis, Ortho-McNeil, McNeil Pharmaceuticals, Pharmacia, and Wyeth-Ayerst; has been a consultant for AstraZeneca, GlaxoSmithKline, McNeil Pharmaceuticals, Merck & Co., Inc., Novartis, Ortho-McNeil, and Wyeth-Ayerst; and is on the speakers’ bureaus of Merck & Co., Inc., Ortho-McNeil, and Wyeth-Ayerst.

Dr. Hochberg has indicated that he has received grant or research support from Merck & Co., Inc., and has been a consultant for Merck & Co., Inc., and Novartis.

Thomas J. Schnitzer, MD, PhD
Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago

Marc C. Hochberg, MD, MPH
Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore

Correspondence: Thomas J. Schnitzer, MD, PhD, Professor of Medicine, Director, Office of Clinical Research and Training, Northwestern University School of Medicine, 710 North Lake Shore Drive, 10th Floor, Chicago, IL 60611; e-mail: tjs@nwu.edu

Dr. Schnitzer has indicated that he has received clinical research support from Merck & Co., Inc., Novartis, Ortho-McNeil, McNeil Pharmaceuticals, Pharmacia, and Wyeth-Ayerst; has been a consultant for AstraZeneca, GlaxoSmithKline, McNeil Pharmaceuticals, Merck & Co., Inc., Novartis, Ortho-McNeil, and Wyeth-Ayerst; and is on the speakers’ bureaus of Merck & Co., Inc., Ortho-McNeil, and Wyeth-Ayerst.

Dr. Hochberg has indicated that he has received grant or research support from Merck & Co., Inc., and has been a consultant for Merck & Co., Inc., and Novartis.

Thomas J. Schnitzer, MD, PhD
Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago

Marc C. Hochberg, MD, MPH
Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore

Correspondence: Thomas J. Schnitzer, MD, PhD, Professor of Medicine, Director, Office of Clinical Research and Training, Northwestern University School of Medicine, 710 North Lake Shore Drive, 10th Floor, Chicago, IL 60611; e-mail: tjs@nwu.edu

Dr. Schnitzer has indicated that he has received clinical research support from Merck & Co., Inc., Novartis, Ortho-McNeil, McNeil Pharmaceuticals, Pharmacia, and Wyeth-Ayerst; has been a consultant for AstraZeneca, GlaxoSmithKline, McNeil Pharmaceuticals, Merck & Co., Inc., Novartis, Ortho-McNeil, and Wyeth-Ayerst; and is on the speakers’ bureaus of Merck & Co., Inc., Ortho-McNeil, and Wyeth-Ayerst.

Dr. Hochberg has indicated that he has received grant or research support from Merck & Co., Inc., and has been a consultant for Merck & Co., Inc., and Novartis.